Last updated on June 2019

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age


Brief description of study

MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more than 60 countries.

The purpose of this study is to compare the immunogenicity of the currently licensed MenACWY vaccine with the investigational MenACWY liquid vaccine aged for different lengths of time by storage at 2-8C.

Clinical Study Identifier: NCT03433482

Find a site near you

Start Over

GSK Investigational Site

Rosiers-d'Egletons, France
  Connect »

GSK Investigational Site

Ekaterinburg, Russian Federation
  Connect »

GSK Investigational Site

Gatchina, Russian Federation
  Connect »

GSK Investigational Site

Moscow, Russian Federation
  Connect »

GSK Investigational Site

Murmansk, Russian Federation
  Connect »

GSK Investigational Site

Saint Petersburg, Russian Federation
  Connect »

GSK Investigational Site

St.Petersburg, Russian Federation
  Connect »

GSK Investigational Site

Tomsk, Russian Federation
  Connect »

GSK Investigational Site

Yaroslavl, Russian Federation
  Connect »

GSK Investigational Site

Bellville, South Africa
  Connect »

GSK Investigational Site

Centelles (Barcelona), Spain
  Connect »

GSK Investigational Site

Hospitalet de Llobregat, Spain
  Connect »

GSK Investigational Site

La Roca Del Valles (Barcelona), Spain
  Connect »

GSK Investigational Site

Quart De Poblet, Valencia, Spain
  Connect »